Rusfertide
TAK-121
PHASE3
Drug Profile
ModalityPeptide
RouteSC
Therapy AreaRare Disease
Peak Sales Est$1500M
Formulations[]
Companies
TAK (ORIGINATOR)100%
Mechanism: Hepcidin mimetic
Expert: Peptide mimetic of hepcidin that reduces iron absorption and erythrocytosis in polycythemia vera.
Everyday: Mimics a natural hormone that controls iron levels in the blood.
Targets: ["FERROPORTIN"]
Programs (1)
| Indication | Stage | Key Study | Regional Status |
|---|
| PV | PHASE3 | VERIFY | [] |
Notes
First-in-class hepcidin mimetic for polycythemia vera. Positive VERIFY Phase 3 results. Reduces need for phlebotomy. Filing expected FY2025-2026.
Data from Supabase · Updated 2026-03-24